Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARM NASDAQ:EVGN NASDAQ:ITRM NASDAQ:UPC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARMCarisma Therapeutics$0.01+1.3%$0.01$0.00▼$0.56$339K0.882,568 shs17,643 shsEVGNEvogene$0.44-10.5%$0.69$0.39▼$1.50$4.28M1.351.47 million shs34.13 million shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/AUPCUniverse Pharmaceuticals$2.95-3.0%$3.03$2.00▼$11.00$1.71M1.6313,446 shs11,028 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARMCarisma Therapeutics-20.00%-62.44%+7,900.00%-75.83%-98.23%EVGNEvogene-1.60%-12.32%-29.86%-42.09%-64.42%ITRMIterum Therapeutics0.00%0.00%0.00%-82.56%-96.82%UPCUniverse Pharmaceuticals+6.67%+5.19%+12.80%+37.87%-19.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARMCarisma Therapeutics$0.01+1.3%$0.01$0.00▼$0.56$339K0.882,568 shs17,643 shsEVGNEvogene$0.44-10.5%$0.69$0.39▼$1.50$4.28M1.351.47 million shs34.13 million shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/AUPCUniverse Pharmaceuticals$2.95-3.0%$3.03$2.00▼$11.00$1.71M1.6313,446 shs11,028 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARMCarisma Therapeutics-20.00%-62.44%+7,900.00%-75.83%-98.23%EVGNEvogene-1.60%-12.32%-29.86%-42.09%-64.42%ITRMIterum Therapeutics0.00%0.00%0.00%-82.56%-96.82%UPCUniverse Pharmaceuticals+6.67%+5.19%+12.80%+37.87%-19.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARMCarisma Therapeutics 2.67Moderate Buy$1.0012,245.68% UpsideEVGNEvogene 2.50Moderate BuyN/AN/AITRMIterum Therapeutics 1.67ReduceN/AN/AUPCUniverse Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CARM, EVGN, UPC, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026UPCUniverse Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/30/2026ITRMIterum Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARMCarisma Therapeutics$10.77M0.03N/AN/A($0.67) per share-0.01EVGNEvogene$3.85M0.99N/AN/A$1.37 per share0.32ITRMIterum Therapeutics$390K4.10N/AN/A($0.15) per share-0.20UPCUniverse Pharmaceuticals$17.86M0.09N/AN/A$99.64 per share0.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARMCarisma Therapeutics-$60.48M$0.730.01N/AN/A-254.28%N/A-192.17%N/AEVGNEvogene-$8.48M-$1.39N/AN/AN/A-638.12%-158.82%-80.37%8/26/2026 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%N/AUPCUniverse Pharmaceuticals-$3.67MN/AN/AN/AN/AN/AN/AN/AN/ALatest CARM, EVGN, UPC, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2026Q1 2026EVGNEvogene-$0.27-$0.60-$0.33-$0.60$0.35 million$0.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCARMCarisma TherapeuticsN/AN/AN/AN/AN/AEVGNEvogeneN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARMCarisma TherapeuticsN/A0.480.48EVGNEvogeneN/A2.792.76ITRMIterum TherapeuticsN/A2.131.96UPCUniverse PharmaceuticalsN/A4.073.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARMCarisma Therapeutics44.27%EVGNEvogene10.40%ITRMIterum Therapeutics9.21%UPCUniverse Pharmaceuticals0.18%Insider OwnershipCompanyInsider OwnershipCARMCarisma Therapeutics6.90%EVGNEvogene7.40%ITRMIterum Therapeutics2.00%UPCUniverse Pharmaceuticals57.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARMCarisma Therapeutics2041.85 million38.91 millionNo DataEVGNEvogene1408.72 million8.07 millionNo DataITRMIterum Therapeutics1053.29 million52.23 millionNot OptionableUPCUniverse Pharmaceuticals220560,000240,000N/ACARM, EVGN, UPC, and ITRM HeadlinesRecent News About These CompaniesUniverse Pharmaceuticals (NASDAQ:UPC) Stock Price Up 0.7% - What's Next?June 18, 2026 | americanbankingnews.comUniverse Pharmaceuticals Stock NewsJune 17, 2026 | benzinga.comHologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection TechnologyJune 16, 2026 | businesswire.comUniverse Pharmaceuticals Incorporation Class AApril 29, 2026 | edition.cnn.comUniverse Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% – Time to Sell?April 25, 2026 | defenseworld.netDUniverse Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share StructureFebruary 11, 2026 | tipranks.comUniverse Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026February 11, 2026 | quiverquant.comQUniverse Pharmaceuticals INC Announces Effective Date of Dual-Class Share StructureFebruary 11, 2026 | globenewswire.comUniverse Pharmaceuticals Inc trading resumesOctober 8, 2025 | msn.comUniverse Pharmaceuticals Inc trading halted, volatility trading pauseOctober 8, 2025 | msn.comUniverse Pharmaceuticals Approves Key Resolutions at 2025 AGMSeptember 3, 2025 | msn.comUniverse Pharmaceuticals Reports Decline in Financial Performance Amid Regulatory ChangesAugust 31, 2025 | theglobeandmail.comUniverse Pharmaceuticals Postpones Annual General Meeting Due to Quorum IssueAugust 26, 2025 | msn.comUniverse Pharmaceuticals Inc. (UPC) Stock Price Today - WSJAugust 7, 2025 | wsj.comPharma Playbook: What Practitioners Can Learn from Early UPC LitigationMay 14, 2025 | ipwatchdog.comIUniverse Pharmaceuticals Reports Full Year 2024 EarningsMay 3, 2025 | finance.yahoo.comUniverse Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025March 20, 2025 | quiverquant.comQUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | gurufocus.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | investing.comUniverse Pharmaceuticals INC Announces Share ConsolidationMarch 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNVIDIA’s Outlook Gains Momentum: Stock Price to FollowBy Thomas Hughes | June 11, 2026Buy CrowdStrike Before the Stock Split? Here's the CaseBy Chris Markoch | June 22, 2026Palo Alto Networks Accelerates Growth 31% on AI DemandBy Thomas Hughes | June 3, 2026CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts EmergeBy Thomas Hughes | June 18, 2026The Biggest Opportunity From SpaceX’s IPO May Surprise YouBy Jeffrey Neal Johnson | June 10, 2026CARM, EVGN, UPC, and ITRM Company DescriptionsCarisma Therapeutics NASDAQ:CARM$0.0081 +0.00 (+1.25%) As of 01:05 PM EasternCarisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Evogene NASDAQ:EVGN$0.44 -0.05 (-10.55%) Closing price 04:00 PM EasternExtended Trading$0.44 0.00 (-0.50%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Iterum Therapeutics NASDAQ:ITRM$0.03 0.00 (0.00%) As of 06/23/2026Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Universe Pharmaceuticals NASDAQ:UPC$2.95 -0.09 (-2.96%) Closing price 04:00 PM EasternExtended Trading$2.81 -0.14 (-4.71%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
